Sector News

Endo could be the next generics player on the hunt for M&A: Analyst

October 4, 2017
Life sciences

Late last month, reports said Impax Labs may be looking to bulk up in the face of industry-wide generics pricing pressure with a deal for Amneal. And at least one analyst thinks it may make sense for Endo to follow suit.

The way RBC Capital Markets’ Randall Stanicky sees it, Impax’ “game plan” could be “the answer” for the struggling Endo, which earlier this year recorded a $3.5 billion write-down that it largely attributed to the generics squeeze. And while that idea has met with pushback from investors, it’s “a necessary/exercise consideration that we have gone through with our other generic names to answer the question, ‘what strategically can they do?’” Stanicky wrote to clients this week.

What makes Stanicky think M&A’s the answer for Endo? A few factors. First off, de-levering—the path the company is currently pursuing—is “going to take time,” he wrote late last month. Endo’s management on the company’s Q2 call also said it would be open to looking at deals, and private equity firm TPG Capital is the company’s largest shareholder with 9.92%.

Plus, the similarities between Impax and Endo “are striking but sentiment and share performance could not be more different”—and Stanicky attributes that difference “largely … to anticipated large-scale M&A.”

Impax, which The Wall Street Journal has said could buy Amneal for $2 billion or so, isn’t the only drugmaker turning to M&A during tough times. Bloomberg recently reported that Alvogen’s private equity owners are weighing their options for the New Jersey pharma, and a sale of the company’s U.S. business to Shanghai Pharmaceuticals is on the table.

Endo, meanwhile, is in the middle of what’s been a tough stretch beyond the mammoth write-down. The company—led by CEO Paul Campanelli, who took over for Valeant vet and M&A enthusiast Rajiv de Silva last September—has cut more than 1,000 jobs through three phases of restructuring since last May. The 2017 guidance didn’t live up to expectations, either, which were “already diminished,” Barclays analyst Doug Tsao wrote in February.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).